Neuroscience Biotech Alkermes Sees Narcolepsy R&D as Launchpad for a Range of New Fatigue Therapies

Alkermes is chasing Takeda Pharmaceutical, whose orexin receptor-targeting pill is on track to become first in a new class of narcolepsy medicines. Blair Jackson, chief operating officer of the neuroscience biotech, says Alkermes’s drug offers advantages and also paves the way to bring orexin agonism to other indications. The post Neuroscience Biotech Alkermes Sees Narcolepsy…

Read More

Trump Administration Actions to Curb Data Collection Related to Sexual Orientation and Gender Identity (SOGI)

This brief describes Trump Administration efforts to scale back or modify data collection on sexual orientation and gender identity variables in federal surveys. It specifically focuses on changes in three national surveys that are representative of these efforts: the National Health Interview Survey (NHIS), the Medicare Current Beneficiary Survey (MCBS), and the National Crime Victimization…

Read More

Will Trump’s Team Slow Supersized Health Mergers?

Rising health care costs and the impending expiration of expanded Obamacare subsidies fueled the record-setting government shutdown that ended this week.  But there’s another driver of escalating costs and prices playing out in a far broader, more impactful way: the rapid consolidation of insurers, hospital systems, doctors’ groups, and pharmacies into behemoths, effectively giving them…

Read More